2002 Leads Pharmaceutical research Safety 
PharmaKinnex
AUGUST 23, 2022
More convenience and safety? PharmaKinnex knows that identifying, qualifying, and then directing leads toward a successful sale is extremely difficult in today’s environment. As the pandemic ramped up, patients and prescribers ditched their traditional methods of interacting within the office and telemedicine became the new norm.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Expert insights. Personalized for you.
52 
Let's personalize your content